Drugs / HRS-9190
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT07494175 | Apr → May 2026 overdue | — | Jiangsu HengRui Medicine Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 1 | NCT07142850 | Aug → Oct 2025 | — | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT06932315 | Apr → Aug 2025 | — | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT07446309 | Apr → Jul 2026 | — | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT07404579 | Mar → May 2026 | — | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT07733245 | Sep → Dec 2026 expected | — | The Third Xiangya Hospital of Central South University | Enrolling by invitation | No outcome recorded |
| Phase 3 | NCT07746726 | Sep → Dec 2026 expected | — | Jiangsu HengRui Medicine Co., Ltd. | Recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT07252921 Comparator | Oct → Dec 2025 | — | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HRS-9190 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07494175 ↗ |
| Known as | [14C] HRS-9190 | “\[14C\] HRS-9190 for injection” NCT07494175 ↗ |
| Route | Intravenous | “after intravenous bolus injection and continuous intravenous infusion” NCT07142850 ↗ |